Sickle cell anemia is a genetic blood disorder where a single mutation in the hemoglobin gene transforms normal, flexible red blood cells into rigid, crescent-shaped cells that clog blood vessels, starve tissues of oxygen, and break apart prematurely. Diagnosis starts with a simple blood test — usually hemoglobin electrophoresis — and in the U.S., every newborn is screened at birth. Treatment ranges from hydroxyurea (which can cut pain crises by up to 50%) to bone marrow transplant, the only current cure. Prevention focuses on genetic counseling, newborn screening, and — for those already living with the disease — avoiding the triggers that set off vaso-occlusive crises.
Because those vaso-occlusive triggers shape daily life, patients and caregivers often benefit from a closer look at sickle cell symptoms and pain crises and how clinicians manage them.
Because sickle cell anemia is one of many conditions that damage or deform oxygen-carrying cells, it helps to see how it fits among other red blood cell diseases that clinicians diagnose and manage.
Roughly 100,000 Americans live with sickle cell disease, and the World Health Organization estimates over 300,000 babies are born with it worldwide each year. Despite those numbers, sickle cell anemia remains underfunded and underrecognized compared to other genetic conditions. Here’s what you actually need to know about the cells themselves, how doctors diagnose the disease, and what treatment and prevention options look like in 2024.
What Happens Inside Sickle Cell Anemia Cells?
Normal red blood cells are disc-shaped, pliable, and survive about 120 days in circulation. In sickle cell anemia, a point mutation substitutes valine for glutamic acid at position 6 of the beta-globin chain, producing hemoglobin S (HbS). When HbS releases oxygen, it polymerizes into stiff fibers that distort the cell into a sickle shape.
These sickled cells only survive 10–20 days instead of 120, which is why patients are chronically anemic (hemoglobin typically runs 6–8 g/dL). Worse, the rigid cells clump together and stick to blood vessel walls, triggering the hallmark vaso-occlusive pain crises that can land patients in the hospital for days.
Symptoms You Shouldn’t Ignore
- Pain crises (vaso-occlusive episodes): Sudden, severe pain in the chest, abdomen, joints, or bones — the #1 reason for ER visits
- Chronic anemia: Fatigue, pallor, shortness of breath, dizziness
- Dactylitis: Painful swelling of the hands and feet, often the first sign in infants (typically appears by 6 months of age)
- Frequent infections: The spleen often stops functioning by age 5 (autosplenectomy), leaving patients vulnerable to encapsulated bacteria like Streptococcus pneumoniae
- Acute chest syndrome: Chest pain, fever, cough, and a new pulmonary infiltrate on X-ray — this is a medical emergency
- Stroke: Affects up to 11% of children with sickle cell disease by age 20
- Vision changes: Sickle cell retinopathy from blocked retinal blood vessels
Causes and Genetic Risk Factors
Sickle cell anemia follows an autosomal recessive inheritance pattern. You need two copies of the HbS gene — one from each parent — to have the disease. Carrying one copy makes you a sickle cell trait carrier (HbAS), which usually causes no symptoms but does confer some protection against malaria.
When two carriers have a child, each pregnancy carries a 25% chance of sickle cell anemia, a 50% chance of sickle cell trait, and a 25% chance of completely normal hemoglobin. The disease disproportionately affects people of African, Mediterranean, Middle Eastern, and South Asian descent — populations where malaria has historically been endemic.
Diagnosis of Sickle Cell Anemia Cells
In the United States, every state includes sickle cell disease in its newborn screening panel. A heel-prick blood sample is analyzed using hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) to identify HbS.
| Test | What It Detects | When It’s Used |
|---|---|---|
| Hemoglobin electrophoresis | Separates hemoglobin types (HbA, HbS, HbF, HbC) | Newborn screening, confirmatory testing |
| HPLC | Quantifies hemoglobin fractions | Newborn screening, monitoring HbF levels on hydroxyurea |
| Peripheral blood smear | Sickled cells, target cells, Howell-Jolly bodies | Initial workup, crisis evaluation |
| Solubility test (Sickledex) | Detects presence of HbS | Rapid screening (does NOT distinguish trait from disease) |
| Genetic testing | Identifies specific beta-globin mutations | Prenatal diagnosis, carrier testing, ambiguous cases |
| Prenatal testing (CVS/amniocentesis) | Fetal DNA analysis for HbS mutation | High-risk pregnancies (both parents are carriers) |
Prenatal diagnosis is available as early as 10–12 weeks via chorionic villus sampling (CVS). For couples who are both carriers, this allows informed decision-making before birth.
Treatment Options for Sickle Cell Anemia
Disease-Modifying Therapies
Hydroxyurea remains the backbone of sickle cell treatment. It boosts fetal hemoglobin (HbF) production, which inhibits HbS polymerization. Clinical trials show it reduces pain crises by 44–50%, cuts hospitalizations, and decreases mortality. The FDA approves it for adults and children as young as 2 years old, though many hematologists start it even earlier.
L-glutamine (Endari), approved in 2017, reduces oxidative stress in sickled cells and lowers crisis frequency by about 25%. Voxelotor (Oxbryta) directly inhibits HbS polymerization, raising hemoglobin levels by approximately 1 g/dL. Crizanlizumab (Adakveo) is a monoclonal antibody targeting P-selectin that reduces vaso-occlusive crises by blocking cell adhesion to vessel walls.
Gene Therapy: A New Frontier
In December 2023, the FDA approved two gene therapies for sickle cell disease: Casgevy (the first CRISPR-based therapy ever approved) and Lyfgenia. Both require myeloablative conditioning and autologous stem cell transplant, and early results show the majority of treated patients become crisis-free. The price tag — roughly $2.2 million per patient — remains a significant barrier.
Bone Marrow Transplant
Allogeneic hematopoietic stem cell transplant (HSCT) from a matched sibling donor has cure rates exceeding 90% in children. The catch: only about 18% of patients have a fully matched sibling donor. Haploidentical transplant protocols are expanding the donor pool, but transplant-related mortality remains a real risk, especially in adults.
Supportive Care
- Chronic blood transfusions: Used primarily for stroke prevention in children with abnormal transcranial Doppler (TCD) velocities >200 cm/s
- Penicillin prophylaxis: Started by 2 months of age and continued until at least age 5 to prevent pneumococcal sepsis
- Folic acid supplementation: 1 mg daily to support red blood cell production
- Pain management: NSAIDs for mild crises; IV opioids and fluids for severe episodes
- Vaccinations: Pneumococcal, meningococcal, Haemophilus influenzae type b, and annual influenza vaccines are essential
Prevention Strategies
You can’t change your genes, but there are two levels of prevention that matter here:
Preventing the Disease
- Genetic counseling: Carrier testing for at-risk couples before conception. A simple hemoglobin electrophoresis identifies carriers.
- Prenatal testing: CVS or amniocentesis for pregnancies where both parents carry HbS.
- Preimplantation genetic diagnosis (PGD): For couples using IVF, embryos can be tested for HbS before implantation.
Preventing Complications in Patients with Sickle Cell Disease
- Stay well-hydrated (dehydration concentrates HbS and triggers sickling)
- Avoid extreme temperatures, high altitude, and unpressurized aircraft
- Take hydroxyurea consistently — adherence is everything
- Get annual TCD screening (ages 2–16) to catch stroke risk early
- Annual eye exams starting at age 10 for sickle cell retinopathy
- Avoid smoking and excessive alcohol
When to Go to the Emergency Room
Sickle cell disease can turn life-threatening quickly. Seek emergency care for:
- Fever above 101.3°F (38.5°C) — treat as sepsis until proven otherwise due to functional asplenia
- Chest pain with shortness of breath or cough (acute chest syndrome kills)
- Sudden weakness, slurred speech, or severe headache (stroke)
- Pain crisis not responsive to home medications
- Sudden enlargement of the spleen with worsening anemia (splenic sequestration — most common in children under 5)
- Priapism lasting more than 4 hours
Frequently Asked Questions
Can you have sickle cell trait and never know it?
Yes. Most of the roughly 3 million Americans with sickle cell trait (HbAS) are completely asymptomatic. Trait carriers have one normal and one mutant gene, so they produce both HbA and HbS. Under extreme conditions — severe dehydration, high altitude, intense exercise — some carriers can experience complications, but this is uncommon. If you haven’t been tested and belong to a high-risk ethnic group, ask your doctor for hemoglobin electrophoresis.
What’s the life expectancy for someone with sickle cell anemia?
Median survival has improved dramatically — from under 20 years in the 1970s to 43–54 years in the U.S. today, thanks to newborn screening, penicillin prophylaxis, and hydroxyurea. Gene therapy and improved transplant protocols may push this further. In low-resource settings without access to these interventions, up to 50–90% of children with sickle cell disease still die before age 5.
Is sickle cell anemia the same as sickle cell disease?
Not exactly. Sickle cell disease is the umbrella term covering all genotypes that cause sickling, including HbSS (sickle cell anemia), HbSC, HbS-beta thalassemia, and others. Sickle cell anemia specifically refers to HbSS — the most severe form, where both beta-globin genes produce HbS. HbSC disease and HbS-beta+ thalassemia tend to be milder but still cause real problems.
Does sickle cell trait protect against malaria?
Yes. Carriers of sickle cell trait have roughly a 60% reduced risk of severe Plasmodium falciparum malaria. This survival advantage is why the HbS mutation persists at high frequency in malaria-endemic regions — a textbook example of balanced polymorphism in human genetics.
Can adults get a bone marrow transplant for sickle cell disease?
They can, but outcomes are less favorable than in children. Graft-versus-host disease, graft rejection, and transplant-related mortality are higher in adults. Current research on reduced-intensity conditioning regimens and haploidentical donors is making adult transplant safer, and the new gene therapies (Casgevy and Lyfgenia) are approved for patients aged 12 and older — potentially changing the landscape for adults who lack matched donors.
